<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734835</url>
  </required_header>
  <id_info>
    <org_study_id>13678</org_study_id>
    <nct_id>NCT03734835</nct_id>
  </id_info>
  <brief_title>The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Metabolic Syndrome</brief_title>
  <official_title>The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Metabolic Syndrome and Its Components: A Randomized, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of Hesperidin, flaxseed and both together in patients with metabolic
      syndrome, 100 patients will be randomly allocated to one of following four groups: control
      group, hesperidin group (2 capsules Hesperidin), flaxseed group (30 gram flaxseed) or
      flaxseed-hesperidin group (2 capsules Hesperidin and 30 gram flaxseed) for 12 weeks; both
      groups will be advised to adherence the investigators' diet and exercise program too. At the
      first and the end of the intervention, metabolic factors will be assessed and compared
      between groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic syndrome: Number of participants with treated metabolic syndrome</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants with treated metabolic syndrome</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>hesperidin and flaxseed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg hesperidin as two capsules and 30 grams flaxseed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flaxseed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 grams flaxseed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hesperidin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg hesperidin as two capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>hesperidin</intervention_name>
    <description>1000 mg hesperidin as two capsules</description>
    <arm_group_label>hesperidin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>hesperidin and flaxseed</intervention_name>
    <description>1000 mg hesperidin as two capsules and 30 grams flaxseed</description>
    <arm_group_label>hesperidin and flaxseed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flaxseed</intervention_name>
    <description>30 grams flaxseed</description>
    <arm_group_label>flaxseed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>no supplementation</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 to 70 years

          -  having 3 of 5 of high blood sugar, hypertension, high TG, high waist circumference,
             low HD

        Exclusion Criteria:

          -  pregnancy or lactation

          -  history of Cardiovascular disease, Pulmonary disease, Renal disease &amp; Celiac disease;
             Cirrhosis

          -  Following a program to lose weight in recent 3 mo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>azita Hekmatdoost, MD.PhD</last_name>
    <phone>+982122357484</phone>
    <email>a_hekmat2000@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Nutrition and Food Technology Research Institute</name>
      <address>
        <city>Tehran</city>
        <state>Iran (the Islamic Republic Of)</state>
        <zip>1981619573</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azits Hekmatdoost, MD,PhD</last_name>
      <phone>+982122357484</phone>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

